Elzbieta Drozdowicz
Research Subjects
Elzbieta Drozdowicz has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Varol
Roche Innovation Center Zürich (RICZ), Zürich, Switzerland
17 shared publications - Alberto Valdeolivas
Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
17 shared publications - Ana Amorim
Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland
17 shared publications - Benedek Pesti
Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
17 shared publications - Birte Appelt
Roche Innovation Center Zürich (RICZ), Zürich, Switzerland
17 shared publications - Christian Gassner
Roche Innovation Center Munich (RICM), Munich, Switzerland
17 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Changes in abundance of various cell populations in tumors upon treatment with FAP-LTBR.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Changes in abundance of various cell populations in tumors upon treatment with FAP-LTBR.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Schematic representation of the study design described in Figure 4 and 5. Average relative expression levels across samples for top differentially expressed genes in muFAP-LTBR vs control treatment.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Schematic representation of the study design described in Figure 4 and 5. Average relative expression levels across samples for top differentially expressed genes in muFAP-LTBR vs control treatment.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
List of antibodies used for imaging and flow cytometry.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
List of antibodies used for imaging and flow cytometry.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
List of differentially regulated genes upon treatment with FAP-LTBR.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
List of differentially regulated genes upon treatment with FAP-LTBR.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Details of the tumor volumes and Tumor vs Stromal content of selected tumors used for spatial transcriptomics.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Details of the tumor volumes and Tumor vs Stromal content of selected tumors used for spatial transcriptomics.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Images show accumulation of T cells around HEVs in the muFAP-LTBR treated mice bearing AKPS CRC tumors.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Images show accumulation of T cells around HEVs in the muFAP-LTBR treated mice bearing AKPS CRC tumors.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Differential gene expression results upon muFAP-LTBR treatment in stromal or tumor regions.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Differential gene expression results upon muFAP-LTBR treatment in stromal or tumor regions.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S9 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Schematic detailing and results from the in vivo study with BC004 tumor model in humanized mice treated with FAP-LTBR and FolR1 TCB in monotherapy and in combination.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S9 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Schematic detailing and results from the in vivo study with BC004 tumor model in humanized mice treated with FAP-LTBR and FolR1 TCB in monotherapy and in combination.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Schematic representation and properties of muFAP-LTBR. IHC staining of FAP and LTBR expression in EMT6 mouse tumors. Study design and kinetics of LTBR expression upon treatment.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Schematic representation and properties of muFAP-LTBR. IHC staining of FAP and LTBR expression in EMT6 mouse tumors. Study design and kinetics of LTBR expression upon treatment.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S7 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Schematic detailing and results from the in vivo study with EMT6 tumor model treated with DP47-LTBR and FAP-LTBR molecules.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S7 from FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors
Schematic detailing and results from the in vivo study with EMT6 tumor model treated with DP47-LTBR and FAP-LTBR molecules.